Table 3.
Summary of immunogenicity against variants of concern between heterologous and homologous prime-boost schedules at 28 days after boost
|
Prime with ChAd |
Prime with BNT |
|||||
|---|---|---|---|---|---|---|
| ChAd/ChAd (n=47) | ChAd/m1273 (n=48) | ChAd/NVX (n=51) | BNT/BNT (n=46) | BNT/m1273 (n=48) | BNT/NVX (n=49) | |
| Live virus neutralising antibody (Victoria*), FRNT50 | ||||||
| n | 47 | 48 | 51 | 46 | 48 | 49 |
| GMC | 109 (70–168) | 1684 (1313–2162) | 432 (301–618) | 1501 (1188–1896) | 1883 (1546–2294) | 1109 (805–1529) |
| GMR† | Ref | 16·9 (10·1–28·0) | 4·2 (2·4–7·2) | Ref | 1·3 (1·0–1·8) | 0·8 (0·6–1·2) |
| Live virus neutralising antibody (beta), FRNT50 | ||||||
| n | 47 | 48 | 51 | 46 | 48 | 49 |
| GMC | 25 (18–34) | 376 (260–545) | 109 (71–167) | 405 (290–565) | 603 (442–822) | 451 (305–666) |
| GMR† | Ref | 15·8 (9·6–26·1) | 4·2 (2·4–7·4) | Ref | 1·6 (1·0–2·5) | 1·3 (0·8–2·2) |
| Live virus neutralising antibody (delta), FRNT50 | ||||||
| n | 47 | 48 | 51 | 46 | 48 | 49 |
| GMC | 41 (27–64) | 672 (506–891) | 153 (99–237) | 697 (520–933) | 873 (688–1107) | 629 (444–891) |
| GMR† | Ref | 17·4 (10·2–29·5) | 3·7 (2·0–6·9) | Ref | 1·3 (0·9–2·0) | 1 (0·7–1·6) |
| Cellular response (wild-type, frozen samples), SFC per million PBMCs | ||||||
| n | 44 | 47 | 50 | 44 | 44 | 46 |
| GMC | 41 (27–62) | 100 (73–136) | 160 (129–198) | 35 (25–49) | 71 (52–97) | 20 (14–29) |
| GMR† | Ref | 2·9 (1·8–4·6) | 4·5 (3·0–6·8) | Ref | 1·9 (1·2–3·0) | 0·60 (0·4–1·0) |
| Cellular response (beta, frozen samples), SFC per million PBMCs | ||||||
| n | 44 | 47 | 50 | 44 | 44 | 46 |
| GMC | 41 (28–60) | 104 (77–141) | 150 (120–187) | 34 (23–48) | 69 (52–92) | 22 (17–30) |
| GMR† | Ref | 3·1 (2·0–4·7) | 4·2 (2·9–6·0) | Ref | 2·0 (1·2–3·1) | 0·72 (0·46–1·1) |
| Cellular response (delta, frozen samples), SFC per million PBMCs | ||||||
| n | 44 | 47 | 50 | 44 | 44 | 46 |
| GMC | 35 (23–54) | 102 (76–136) | 155 (123–196) | 36 (26–51) | 64 (47–86) | 19 (13–28) |
| GMR† | Ref | 3·4 (2·1–5·4) | 5·0 (3·3–7·6) | Ref | 1·6 (1·0–2·5) | 0·56 (0·3–0·9) |
Data shown are geometric mean (95% CI), unless otherwise specified. BNT=BNT162b2 vaccine, Pfizer–BioNTech. ChAd=ChAdOx1 nCoV-19 vaccine, AstraZeneca. ELU=ELISA laboratory units. FRNT50=50% focus reduction neutralising antibody titre. GMC=geometric mean concentration. GMR=geometric mean ratio. m1273=mRNA-1273 vaccine, Moderna. NVX=NVXCoV2373 vaccine, Novavax. PBMCs=peripheral blood mononuclear cells. SFC=spot-forming cells.
A Wuhan-related strain isolated early in the pandemic from Australia.
The two-sided 95% CIs of GMRs were adjusted for study site, cohort, interval between first and second dose, and baseline immunogenicity.